COGT241220C5000
- 5.60
- 0.000.00%
Cogent Biosciences Newsroom
Piper Sandler Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $23
Express News | Cogent Biosciences Inc : Guggenheim Cuts Target Price to $17 From $20
J.P. Morgan Maintains Cogent Biosciences(COGT.US) With Buy Rating, Raises Target Price to $21
Cogent Biosciences Is Maintained at Buy by Needham
Needham Maintains Cogent Biosciences(COGT.US) With Buy Rating, Cuts Target Price to $15
Express News | Cogent Biosciences Inc : Needham Cuts Target Price to $15 From $16
Cogent Biosciences: Buy Rating Affirmed Amid Anticipation for Bezuclastinib Data and Strong Financial Position
Cogent Biosciences Reports Progress in Clinical Trials and Financial Standing
Cogent Biosciences | 8-K: Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2024 Financial Results
Cogent Biosciences | 10-Q: Q3 2024 Earnings Report
Express News | Cogent Biosciences Inc: Strong Cash Position of $346 Mln Sufficient to Fund Operations Into Late 2026
Express News | Cogent Biosciences Inc: Top-Line Results From Registration-Directed Summit, Peak and Apex Trials Expected in 2025
Cogent Biosciences Reports Q3 EPS (64c), Consensus (57c)
Express News | Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2024 Financial Results
Express News | Cogent Biosciences Q3 Operating Expenses USD 75.414 Million
Press Release: Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2024 Financial Results
Cogent Biosciences 3Q Loss/Shr 64c >COGT
Citi Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $15
LifeSci Capital Maintains Cogent Biosciences(COGT.US) With Buy Rating, Maintains Target Price $16
Buy Recommendation for Cogent Biosciences Amid Unjustified Stock Decline